BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Felcorekibart readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Felcorekibart\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07712393-3551@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20270413
DTEND;VALUE=DATE:20270414
SUMMARY:Felcorekibart: Phase 1 readout est. (NCT07712393)
DESCRIPTION:Felcorekibart\, phase 1\, Asthma.\nStudy: A Comparative Study t
 o Investigate the Difference in Blood Levels of Two Different Formulations
  of GSK5784283\nEstimated primary completion: 13 April 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/felcorekibart#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07712393
URL:https://assetmemo.bio/drug/felcorekibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07098403-3551@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Felcorekibart: Phase 3 readout est. (NCT07098403)
DESCRIPTION:Felcorekibart\, phase 3\, Asthma.\nStudy: A Trial of SHR-1905 i
 n Subjects With Severe Uncontrolled Asthma\nEstimated primary completion: 
 January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/felcore
 kibart#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07098403
URL:https://assetmemo.bio/drug/felcorekibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07132827-3551@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Felcorekibart: Phase 3 readout est. (NCT07132827)
DESCRIPTION:Felcorekibart\, phase 3.\nStudy: Efficacy and Safety of SHR-190
 5 Injection in Subjects With Chronic Rhinosinusitis With Nasal Polyps\nEst
 imated primary completion: April 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/felcorekibart#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07132827
URL:https://assetmemo.bio/drug/felcorekibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07780643-3551@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20290215
DTEND;VALUE=DATE:20290216
SUMMARY:Felcorekibart: Phase 3 readout est. (NCT07780643)
DESCRIPTION:Felcorekibart\, phase 3\, Asthma.\nStudy: A Study to Investigat
 e the Efficacy and Safety of GSK5784283 Compared With Placebo in Participa
 nts With Uncontrolled Asthma (PERSIST ASTHMA-1)\nEstimated primary complet
 ion: 15 February 2029. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/felcorekibart#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07780643
URL:https://assetmemo.bio/drug/felcorekibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07782957-3551@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20290306
DTEND;VALUE=DATE:20290307
SUMMARY:Felcorekibart: Phase 3 readout est. (NCT07782957)
DESCRIPTION:Felcorekibart\, phase 3.\nStudy: A Study to Assess the Efficacy
  and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Partici
 pants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)\nEstimated pr
 imary completion: 6 March 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/felcorekibart#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07782957
URL:https://assetmemo.bio/drug/felcorekibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07782970-3551@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20290306
DTEND;VALUE=DATE:20290307
SUMMARY:Felcorekibart: Phase 3 readout est. (NCT07782970)
DESCRIPTION:Felcorekibart\, phase 3.\nStudy: A Study to Assess the Efficacy
  and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhi
 nosinusitis With Nasal Polyps (CRSwNP)\nEstimated primary completion: 6 Ma
 rch 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/felcorekiba
 rt#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7782970
URL:https://assetmemo.bio/drug/felcorekibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07915791-3551@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20290307
DTEND;VALUE=DATE:20290308
SUMMARY:Felcorekibart: Phase 2 readout est. (NCT07915791)
DESCRIPTION:Felcorekibart\, phase 2\, Chronic Obstructive Pulmonary Disease
 .\nStudy: A Study to Assess the Efficacy and Safety of Co-administration o
 f GSK3862995B With GSK5784283 in Adult Participants With Moderate to Sever
 e Chronic Obstructive Pulmonary Disease (COPD)\nEstimated primary completi
 on: 7 March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fel
 corekibart#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07915791
URL:https://assetmemo.bio/drug/felcorekibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07782996-3551@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20290504
DTEND;VALUE=DATE:20290505
SUMMARY:Felcorekibart: Phase 3 readout est. (NCT07782996)
DESCRIPTION:Felcorekibart\, phase 3\, Asthma.\nStudy: A Study to Investigat
 e the Efficacy and Safety of GSK5784283 Compared With Placebo in Participa
 nts With Uncontrolled Asthma (PERSIST ASTHMA-2)\nEstimated primary complet
 ion: 4 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/felc
 orekibart#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07782996
URL:https://assetmemo.bio/drug/felcorekibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07780656-3551@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20290720
DTEND;VALUE=DATE:20290721
SUMMARY:Felcorekibart: Phase 3 readout est. (NCT07780656)
DESCRIPTION:Felcorekibart\, phase 3\, Chronic Obstructive Pulmonary Disease
 .\nStudy: A Study to Investigate the Efficacy and Safety of GSK5784283 (Fe
 lcorekibart) Compared With Placebo in Participants With Moderate to Very S
 evere COPD (PERSIST COPD-2)\nEstimated primary completion: 20 July 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/felcorekibart#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07780656
URL:https://assetmemo.bio/drug/felcorekibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07780669-3551@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20290720
DTEND;VALUE=DATE:20290721
SUMMARY:Felcorekibart: Phase 3 readout est. (NCT07780669)
DESCRIPTION:Felcorekibart\, phase 3\, Chronic Obstructive Pulmonary Disease
 .\nStudy: A Study to Investigate the Efficacy and Safety of GSK5784283 (Fe
 lcorekibart) Compared With Placebo in Participants With Moderate to Very S
 evere COPD (PERSIST COPD-1)\nEstimated primary completion: 20 July 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/felcorekibart#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07780669
URL:https://assetmemo.bio/drug/felcorekibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
